2026-04-13T16:39:14Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/130362025-05-08T02:09:19Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Tchang, Beverly
author
Stefanski, Adam
author
Garcia Perez, Luis Emilio
author
Mojdami, Donna
author
Jouravskaya, Irina
author
Ciudin Mihai, Andreea
2025-05-06T10:04:37Z2025-05-06T10:04:37Z2025-05
Body weight reduction; Women; Reproductive stageReducción del peso corporal; Mujeres; Etapa reproductivaReducció del pes corporal; Dones; Etapa reproductivaObjective
Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage.
Methods
Women participants from SURMOUNT-1, -3, and -4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre-, peri-, or post-menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight-reduction thresholds, and waist to height ratio (WHtR) category shift among those with baseline BMI < 35 kg/m2 were assessed at end of study treatment.
Results
In SURMOUNT-1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/m2 reached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT-3 and -4.
Conclusions
In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.Funding for this post hoc analysis was provided by Eli Lilly and Company.
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Dones
Menopausa
Tractaments d'aprimament
Aprimament
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Obesity Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss
PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause
PHENOMENA AND PROCESSES::Physiological Phenomena::Body Constitution::Body Composition::Body Fat Distribution::Adiposity
NAMED GROUPS::Persons::Women
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos antiobesidad
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::cambios en el peso corporal::pérdida de peso
FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::climaterio::menopausia
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::constitución corporal::composición corporal::distribución de la grasa corporal::adiposidad
DENOMINACIONES DE GRUPOS::personas::mujeres
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion